These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35797004)

  • 21. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.
    Buse JB; Bode BW; Mertens A; Cho YM; Christiansen E; Hertz CL; Nielsen MA; Pieber TR;
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33318068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.
    Brooks A; Langer J; Tervonen T; Hemmingsen MP; Eguchi K; Bacci ED
    Diabetes Ther; 2019 Apr; 10(2):735-749. PubMed ID: 30847838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.
    Gelhorn HL; Osumili B; Brown K; Ross MM; Schulz A; Fernandez G; Boye KS
    Patient Prefer Adherence; 2023; 17():793-805. PubMed ID: 36987498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic treatment of type 2 diabetes: injectable medications.
    Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
    Ann Pharmacother; 2015 Jun; 49(6):700-14. PubMed ID: 25802244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
    Paquot N
    Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Semaglutide Reduces HbA
    Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
    Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Campos C; Unger J
    Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic treatment of type 2 diabetes: oral medications.
    Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
    Ann Pharmacother; 2015 May; 49(5):540-56. PubMed ID: 25667196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.